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Objective: To investigate the impacts of vitamin D status, supplementation and vitamin D receptor (VDR)
gene polymorphisms on tuberculosis (TB).
Methods: We conducted a systematic review of published studies pertaining to caseecontrol and
randomized-control trials from 2002 to 2014 using the PubMed database.
Results and conclusion: Individuals with TB have lower vitamin D status than healthy individuals. Some
VDR gene polymorphisms are associated with increased susceptibility to TB while others may not.
Supplementation with vitamin D leads to improved clinical outcomes. However, further studies with a
larger patient population and different ethnicities are needed to conﬁrm these effects.
 2014 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license.Introduction
Tuberculosis (TB) remains a great burden throughout the world
to this date. According to the latestWorld Health Organization data,
an estimated 8.6 million individuals developed TB and 1.3 million
died as a result of this disease in 2012. The majority of these cases
occurred in South-East Asia (29%), Africa (27%), and the Western
Paciﬁc (17%). India and China accounted for 26% and 12% of the total
cases, respectively. Furthermore, an estimated 1.1 million of the 8.6
million individuals who developed TB were also HIV-positive [1].
Vitamin D has been known to play an important role in bone
health for almost a century [2]. However, the extra-skeletal roles of
vitamin D have only received attention during the past two de-
cades, which includes vitamin D’s role in human innate immunityoxyvitamin D; 1a,25(OH)2D,
WT homo, wild-type homo-
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BY-NC-ND license (http://
þ1 413 254 9778.
Inc. Open access under CC BY-NC-ND lic[3]. This particular role of vitamin D is especially important in the
body’s defense against tuberculosis through its action on enhancing
macrophage-mediated eradication of Mycobacterium tuberculosis
[4]. Vitamin D, either endogenously produced (vitamin D3) or
ingested (vitamin D2 or vitamin D3), must be activated in order to
produce its effects (Figure 1) [5]. Upon entering the bloodstream,
vitamin D is delivered to the liver, where it undergoes the ﬁrst
hydroxylation to become 25-hydroxyvitamin D (25(OH)D), the
main circulating form of vitamin D. From the liver, the 25(OH)D
travels to the kidney, where it undergoes another hydroxylation to
become 1a,25-dihydroxyvitamin D (1a,25(OH)2D), which is the
active form. Upon undergoing the second hydroxylation, vitamin D
is now able to regulate transcription of genes throughout the body.
However, new evidence has been accumulated indicating that
25(OH)D and 1a,25(OH)2D can be synthesized in tissues other than
the liver and kidneys, respectively [5e7].
It has been shown that vitamin D deﬁciency [8] (serum 25(OH)D
level <20 ng/mL or <50 nmol/L) and insufﬁciency [8] (serum
25(OH)D level <30 ng/mL or <75 nmol/L) are associated with a
higher risk of active TB [9], suggesting that low serum 25(OH)D
levels may also lead to prolonged clinical course of the disease if not
corrected. Therefore, it is appropriate to surmise that individuals
with higher levels of circulating 25(OH)D are associated with betterense.
Figure 1. Photosynthesis and cytochrome P-450 enzyme-dependent metabolism of vitamin D3. Humans receive most of their vitamin D requirement from the exposure of their skin
to sunlight while a minor portion may obtained from dietary sources, such as fortiﬁed milk and oily ﬁsh. Upon exposure to ultraviolet B wavelengths between 290 and 315 nm,
7-dehydrocholecalciferol (7-DHC) in the skin is photolyzed to form a 9,10-seco-sterol pre-vitamin D3 (Pre-D3), which undergoes a heat-dependent isomerization to form vitamin D3
(D3). D3 produced is speciﬁcally translocated by the vitamin D-binding protein (DBP) into circulation and then to the liver for hydroxylation at carbon-25 to form 25-hydroxyvitamin
D3 (25D3) mainly by two cytochrome P-450 enzymes, CYP2R1 and CYP27A1. Synthesized 25D is then transported to the kidneys after binding to DBP in the bloodstream. In the
kidneys, 25D3 is hydroxylated in the presence of CYP27B1 to 1a,25-dihydroxyvitamin D3 (1,25D3), the active form of vitamin D, which serves as a hormone to regulate a variety of
cellular functions in other organs, or acts inside the kidneys in an autocrine and/or paracrine fashion. 1,25D3 is hydroxylated further by CYP24A1 at carbon-24 to form 1a,24,25-
trihydroxyvitamin D3 (1,24,25D3). The hydroxylation at carbon-24 by CYP24A1 is the ﬁrst step of 1,25D catabolism to terminate its actions, which leads to the formation of cal-
citroic acid, a water soluble metabolite, and excreted into the urine.
N. Sutaria et al. / Journal of Clinical & Translational Endocrinology 1 (2014) 151e160152outcomes with regard to TB, as reported in a previously conduc-
ted systematic review and meta-analysis of seven observational
studies [10].
Along those lines, it can be assumed that increasing vitamin D
intake would help protect against TB, but in reality this is not al-
ways the case. Vitamin D mediates its effect on the innate immune
systemvia the vitamin D receptor (VDR) [Figure 2]. Upon binding to
1a,25(OH)2D, the active form of vitamin D, or its analogs, the VDR
complex moves into the nucleus where it regulates expression of
genes. Among its effects includes increased synthesis of compo-
nents of the innate immune system, such as cathelicidin, which
plays an important role against mycobacterial infections, as well as
other antibacterial, antimycobacterial, and antiviral molecules [3,4].
Autophagy, the digestion of intracellular macromolecules and in-
clusions, is another important cellular function promoted by the
activated VDR [3,4]. This is a particularly important function
involved in clearance of intracellular pathogens, such as mycobac-
teria, as well as neoplastic cells. The activated VDR also plays a role
in regulating the adaptive immune system by inhibiting lympho-
cyte proliferation and reducing production of pro-inﬂammatory
cytokines to prevent excessive responses [11]. It has been previ-
ously shown that VDR gene polymorphisms exist [12], with some
polymorphisms mediating stronger downstream effects than
others. As a result, vitamin D’s effect is dependent on the genotypeof these receptors. As shown in several previous studies, certain
VDR polymorphisms confer increased resistance to TB, while others
make their hosts more susceptible [13,14].
Since TB has long been a burden throughout the world, many
different treatments have been formulated and tested with varying
results, including vitamin D. Several lines of evidence have led to
the use of this seco-steroid. Starting back in 1848, physicians at the
Royal Brompton Hospital in London reported that patients with
consumption, an earlier term for TB, had a higher disease arrest
(18% vs 5%) and survival (81% vs 67%) rate when cod liver oil was
added to the standard therapy regimen [15]. This ﬁnding clearly
suggested that vitamin D could be used in anti-TB therapy as it was
well-known that cod liver oil contained high concentrations of
vitamin D, and was the source where vitamin Dwas discovered and
named by McCollum EV in 1922 [16]. Further implication of the
usefulness of vitamin D in treating TB came from the studies using
heliotherapy during the period between 1928 and 1929 by Howson
[17], Mekie [18], and Rollier [19], andmore recently by Hobday [20],
Sabbatani [21], Willis et al. [22], and Ralph et al. [23]. The connec-
tion of sunlight exposure, vitamin D and chronic diseases has been
extensively discussed [24]. After the discovery of vitamin D and
after pure ergocalciferol (vitamin D2) was available, a case report
from 1947 notes its oral use in the successful treatment of a woman
with cutaneous tuberculosis [25]. This highlights the fact that the
Figure 2. Vitamin D-mediated activation of the innate immune system in macro-
phages (adapted from Adams and Hewison, Nat Clin Pract Endocrinol Metab. 2008;
4(2):80e90. Ref. [3]). Innate immune systems provide the ﬁrst line of defense against
pathogen infection. Upon pathogen detection, such as Mycobacterium tuberculosis (M.
Tuberculosis), toll-like receptors (TLR) on the macrophage membrane are activated to
induce transcriptional up-regulation of the vitamin D receptor (VDR) and enhance
CYP27B1 expression, leading to the increased synthesis of 1,25D and VDR, two essential
components responsible for the VDR-dependent regulation of a variety of genes
including the up-regulation of cathelidicin expression. Incorporation of cathelidicin
into phagosomes containing internalized M. Tuberculosis enables the peptide to
function as an antimicrobial agent to kill the invading pathogen.
N. Sutaria et al. / Journal of Clinical & Translational Endocrinology 1 (2014) 151e160 153anti-mycobacterial effects of vitamin D have been known for quite
some time. More recently, clinical trials have been conducted to
explore the efﬁcacy of vitamin D supplementation in individuals
with TB. Given the data collected from previous studies, one would
expect that supplementation with vitamin D would lead to faster
eradication of the disease. A recent systematic review of
randomized-controlled trials [26] showed mixed results with re-
gard to vitamin D supplementation, urging for more data to be
collected before any deﬁnitive conclusion could be reasonably
made.
The purpose of this systematic review is to analyze newer data
from the past ten years in order to gain insights into the following
questions:
1) Do serum 25(OH)D levels impact the risk of TB?
2) Do different VDR polymorphisms confer distinct degrees of
protection or susceptibility to TB?
3) Does supplementationwith vitamin D in patients with active TB
result in improved outcomes?
Discussion of search and analysis methods
First, we conducted a systematic review of published studies
that investigated the relationship between 25(OH)D serum levels
and TB susceptibility, VDR polymorphisms and TB susceptibility,
and vitamin D supplementation in the treatment of TB. We
reviewed the medical literature in the PubMed online database
from 2002 through 2014. We used a combination of the following
search terms: “vitamin D, vitamin D2, vitamin D3, vitamin D analog,
ergocalciferol, cholecalciferol, tuberculosis, respiratory illness,
bacteria” to ﬁnd studies pertaining to vitamin D status and vitaminD supplementation. In order to ﬁnd studies pertaining to VDR
polymorphisms, the search terms “vitamin D receptor, poly-
morphism, tuberculosis, respiratory illness, bacteria” were used.
The database was restricted to articles published after 2002. The
resulting abstracts were screened and cross-referenced to identify
additional publications pertaining to the subject. Studies that were
written in non-English languages were excluded.
Vitamin D levels and tuberculosis
Results
A total of three hundred and ﬁfty-one articles were identiﬁed
based on the initial PubMed search criteria. No additional articles
were identiﬁed from any other databases. Studies were included if
they were investigating 25(OH)D serum levels in a case-control
fashion. Exclusion criteria included any studies without a control
group or other form of comparison group and if subjects were
previously treated for TB. A total of seven studies [27e33] met the
inclusion and exclusion criteria (Table 1). A total of 6553 individuals
participated in the seven studies combined. All studies were pub-
lished between 2007 and 2014, and all of them compared 25(OH)D
levels in tuberculosis patients and controls.
Four of the studies were based on indigenous Asian populations
and twostudies centeredon indigenousAfricanpopulations. The last
study focused on a predominantly white population in Greenland,
but also included a sizeable portion of the native Inuit population.
All studies investigated untreated TB patients who were to be
initiated on anti-tuberculosis therapy. Six of the seven studies
[27,28,30e33] recruited the case population either as inpatients or
outpatients. Diagnosis was made predominantly by a positive
sputum acid-fast bacilli culture in all of the studies. The remaining
study [29] was a cross-sectional study that selected only a control
group, and then compared this group to TB patients from another
study conducted in the same geographic location.
The control group selection procedures varied between the
different studies. Talat et al. utilized household contacts of their TB
patients [28]. Hong et al. selected healthy, matched controls based
on a Korean nation-wide health survey [27]. Similarly, Mastala et al.
selected control group from a random pool of participants who had
completed a health questionnaire [29]. Ho-pham et al. recruited
healthy controls from a previous study looking at vitamin D status
in the same geographic location [31]. Nielsen et al. [32], Kim et al.
[30], and Wejse et al. [33] all selected healthy controls from the
same hospital/health center used to identify their TB patients.
Case subjects were matched to controls in six of the seven
studies [27e32]. Information regarding potential confounders such
as nutritional status and co-morbidities was provided across all
seven studies. Blood samples were collected during same period for
all subjects across all of the studies. Serum 25(OH)D levels were
measured by radioimmunoassay [27,31,32], tandem mass spec-
trometry [30,33], or ELISA assay [28,29].
Three studies [28e30] reportedmean serum25(OH)D levelswith
corresponding standard deviation. Another study [27] reported
median values with a corresponding range. The remaining three
studies [31e33] investigated the prevalence of vitamin D insufﬁ-
ciency using the same cutoff value of 25(OH)D level <75 nmol/L
(<30 ng/mL). One of the studies [31] looked at the differences in the
prevalence of vitamin D insufﬁciency in men versus women. One
study [28] also investigated progression to fulminant TB in other-
wise healthy household contacts of TB patients.
All seven studies demonstrated that patients with TB had a
lower mean/median serum 25(OH)D level compared to the healthy
controls. Of the three studies looking at the prevalence of vitamin D
insufﬁciency, two studies [31,32] found that prevalence was higher
in TB patients than healthy controls, while the third [32] found no
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alence of vitamin D insufﬁciency was higher in men with TB
compared to healthy men, but determined that women with and
without TB had a similar prevalence of vitamin D insufﬁciency. Talat
et al. [28] illustrated that otherwise healthy contacts of TB patients
had an 8% rate of development of TB, and found that the majority of
this 8% had very low serum 25(OH)D levels.
Discussion
Overall, the data analyzed ﬁnds that individuals with TB have
lower serum levels of 25(OH)D than healthy, age-matched, sex-
matched controls. Since anti-tuberculosis therapy may inadver-
tently cause a decline in 25(OH)D levels, we chose only studies that
investigated untreated individuals.
The similar prevalence of vitamin D insufﬁciency between TB
patients and healthy controls in the study by Wejse et al. may be
due in part to the fact that the chosen controls were unmatched
[33]. Therefore, it is possible that the control group was not
representative of a healthy population without comorbidities.
Additionally, per the authors’ report, dietary intake of the subjects
was not adequately monitored during the entirety of the trial, thus
introducing another potential source of inaccuracy.
The ﬁnding by Ho-pham et al. [31] of the vitamin D insufﬁciency
discrepancy between men and women with and without TB is
notable. They state that the underlying etiology of this difference is
unclear. Potential explanations include the fact that men have a
higher risk of acquiring TB than women, due to socioeconomic and
health care disparities between the two genders. Additionally, there
is evidence showing that estrogen may possibly have protective
effects against TB [34]. Furthermore, the prevalence of smoking in
themale subjects with TBwasmuch higher than in themale control
group. No signiﬁcant difference was found in the female subject
groups with regard to smoking status. Smoking itself is a risk factor
for TB, and smokers aremore likely to have a lower vitamin D intake
than non-smokers [35]. This could potentially account for the dif-
ference seen between both genders in this particular study.
While a relationship between TB and serum 25(OH)D levels has
been established by these studies, it is still inconclusive whether
low vitamin D status (low serum 25(OH)D level) increases the risk
of acquiring TB, or whether TB patients have low vitamin D as a
direct result of the infection. Given the thoroughly elucidated
involvement of vitamin D in the innate immunity pathway, it is
more likely that the former is true. However, the majority of these
studies did not control for diet and/or sunlight exposure. Therefore,
it is difﬁcult to rule out whether the low serum vitamin D levels
existed prior to infection with TB in these patients, or whether
having TB led to poor nutritional intake and more time spent
recuperating indoors, which in turn led to the low serum 25(OH)D
levels (the reverse-causality effect).
Given the implication of vitamin D deﬁciency/insufﬁciency and
risk for TB, many researchers have begun to investigate the effect of
supplementation with vitamin D in tuberculosis patients. The
addition of vitamin D supplements to the standard anti-
tuberculosis drug regimen should theoretically lead to faster reso-
lution of the disease. However, more information must be obtained
before a conclusion can be made. Additionally, it would be beneﬁ-
cial to investigate the effect that vitamin D supplementation has on
incidence of tuberculosis, particularly in high-risk areas around the
world.
Vitamin D receptor gene polymorphisms and tuberculosis
Results
A total of sixty-ﬁve articles studying VDR single nucleotide
polymorphisms (SNPs) in tuberculosis patients were identiﬁedbased on the initial PubMed search criteria. No additional articles
were identiﬁed from any other databases. Studies were included in
the analysis if they investigated VDR polymorphisms with regard to
TB in caseecontrol fashion. Studies were excluded if they did not
investigate the ApaI, BsmI, FokI, and TaqI polymorphisms. A total of
seven studies, described in Table 2, met the inclusion and exclusion
criteria [36e42]. A sum of 2739 individuals participated in the
seven studies combined. All studies were published between 2007
and 2013, and all of them compared the prevalence of different
vitamin D receptor polymorphisms between TB patients and
healthy controls.
Four studies involved subjects of Asian ethnicity, with two
[36,39] focusing on indigenous Chinese population, and the other
two [37,40] focusing on the indigenous Indian population. One
study [38] was centered on the indigenous European population of
Turkey, and yet another study [41] was centered on the indigenous
population of Iran. One study [42] was conducted in South Africa,
and involved mainly the indigenous African population, but also
had a few subjects of Caucasian descent. No other population
groups were involved in these studies.
All studies enrolled TB patients from the primary site of the
study. All patients were newly diagnosed with TB, with the diag-
nosis made predominantly by sputum smear staining, sputum
culture, radiographic ﬁndings, or a combination of these criteria.
One study further divided the case group based on multi-drug
resistant strains of TB versus drug-susceptible strains of TB [37].
All of the studies focused on subjects with pulmonary TB, except for
one study that looked at patients with spinal TB [36].
In ﬁve studies [36e40], controls were chosen from a healthy
pool of age- and sex-matched individuals with similar de-
mographics as the case group. One of these ﬁve studies additionally
recruited household contacts of the case group [40]. Another study
recruited the control group from a pool of age- and sex-matched
doctors, nurses, and TB support staff at the same facility where
the TB patients were recruited [41]. The last study recruited healthy
controls with the same demographics as the case group, but these
individuals were not age-matched or sex-matched [42].
All seven studies investigated some combination of VDR poly-
morphisms. All seven studies investigated FokI. One study investi-
gated ApaI [42], four studies investigated BsmI [37,38,40,41], and
four studies investigated TaqI [37e39,42]. All seven studies utilized
some form of genomic sequencing with restriction fragment length
polymorphism markers to identify the target gene and determine
the polymorphisms. Data collected was reported as number of in-
dividuals in each group with each VDR polymorphism, accompa-
nied by an odds ratio in several of the studies.
Our analysis of the data from these seven studies was pooled
together for each VDR polymorphism, similar towhat previous VDR
studies have done [13,14]. We divided the results into the sub-
groups for both the cases and controls e wild-type (WT), hetero-
zygous (HT), and variant recessive (VR). Subsequently, an odds ratio
was calculated from the pooled data comparing wild-type to
heterozygotes and wild-type to variant recessives for each poly-
morphism and each population studied for that polymorphism.
p-Values were also calculated from the pooled data to determine
signiﬁcance of the odds ratios. Based on this analysis, we deter-
mined that only two of these polymorphisms play a signiﬁcant role
in the risk for tuberculosis (Table 3).
Analysis of the BsmI polymorphism showed that both the het-
erozygous and variant recessive polymorphisms confer an
increased risk of TB as compared to the wild-type form (OR ¼ 1.70
and 1.55, respectively, p < 0.05). Additionally, the FokI recessive
polymorphism showed an increased risk of TB compared to wild-
type (OR ¼ 1.93, p < 0.05). However, the heterozygous form of
FokI showed no signiﬁcant difference over wild-type (p> 0.05). The
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N. Sutaria et al. / Journal of Clinical & Translational Endocrinology 1 (2014) 151e160156ApaI and TaqI heterozygous and recessive polymorphisms showed
no signiﬁcant difference in the risk of TB over their wild-type
counterparts (p > 0.05).
When analyzing the results by ethnicity, it is clear that certain
VDR polymorphisms play different roles in different populations. In
the Asian population, the heterozygous and recessive forms of BsmI
(OR ¼ 1.79 and 2.28, respectively, p < 0.05), the recessive form of
FokI (OR ¼ 2.23, p < 0.05), and the heterozygous form of TaqI
(OR ¼ 1.35, p < 0.05) confer increased susceptibility to TB when
compared to thewild-type form. The heterozygous form of FokI, the
recessive form of TaqI, and neither form of ApaI confer any
increased susceptibility/resistance to TB over the wild-type form. In
the European population, both the heterozygous and recessive
forms of BsmI confer increased resistance to TB when compared to
wild-type (OR¼ 0.32 and 0.15, respectively, p < 0.05). FokI and TaqI
confer no additional increase in susceptibility/resistance compared
to wild-type. ApaI was not studied in this population. In the Middle
Eastern population, both the heterozygous and recessive poly-
morphisms of BsmI confer increased risk of TB over their wild-type
counterparts (OR ¼ 5.93 and 3.07, respectively, p < 0.05). Neither
form of FokI confers any increased susceptibility/resistance to TB
when compared to wild-type. The ApaI and TaqI polymorphisms
were not studied in this population. Lastly, in the African popula-
tion, there was no signiﬁcant increase in susceptibility/resistance to
TB between the heterozygous/recessive forms of ApaI, FokI, and
TaqI and their wild-type counterparts. The BsmI polymorphismwas
not studied in this population.
Discussion
Our review ﬁnds that the individuals carrying BsmI and FokI
VDR polymorphisms showed higher odds of acquiring TB while
those with the ApaI and TaqI VDR polymorphisms did not. Both the
heterozygous and recessive forms of BsmI confer an increased risk
of acquiring TB compared to the wild-type form. Additionally, the
FokI recessive form confers a higher risk compared to its wild-type
counterpart while there is no difference between the heterozygous
and wild-type forms. Notably, when looking at the pooled data, the
FokI variant recessive polymorphism confers the highest risk of
acquiring TB compared to wild-type.
As outlined in the previous section, we have observed that
different ethnic populations may have different susceptibilities and
resistance patterns with regard to the four polymorphisms
analyzed. For instance, BsmI confers the highest risk to the Middle
Eastern and Asian populations, FokI and TaqI confer their highest
risk to the African cohort, and the European subjects show signif-
icant resistance when possessing BsmI. However, as described
further below, it is still too early to draw a conclusion due to the
small sample size of all the studied populations, excluding the Asian
cohort.
In understanding the risks that these different VDR poly-
morphisms portend to the populationwith regard to TB, wemay be
able to effectively comprehend the impacts that vitamin D sup-
plementation may have on treating TB. It is evident that several of
these VDR polymorphisms lead to weaker downstream signaling,
thus weakening the overall effect of vitamin D. Perhaps treatment
with higher doses of vitamin D or its analogs to activate more re-
ceptors and lead to a stronger additive effect would be beneﬁcial in
these patients.
This particular review suffers from the fact that only seven
studies were found that met the inclusion criteria. Due to this, the
ethnic background of each study population limited the analysis of
the different polymorphisms. For example, the ApaI gene was only
investigated in one of the studies we analyzed, and this particular
study was conducted in only the South African population. There-
fore, we cannot conclude that the different ApaI polymorphisms
Table 3
Pooled results from all VDR polymorphism studies
SNP Ethnicity Genotype Cases Controls OR p-Value SNP Ethnicity Genotype Cases Controls OR p-Value
ApaI Total WT homo 101 116 1 BsmI Total WT homo 142 124 1
HT 108 173 0.72 0.07 HT 397 204 1.70 <0.05
VR homo 40 63 0.73 0.2 VR homo 234 132 1.55 <0.05
African WT homo 101 116 1 Asian WT homo 107 106 1
HT 108 173 0.72 0.07 HT 262 145 1.79 <0.05
VR homo 40 63 0.73 0.2 VR homo 159 69 2.28 <0.05
FokI Total WT homo 571 581 1 European WT homo 28 5 1
HT 510 447 1.16 0.09 HT 68 38 0.32 <0.05
VR homo 184 97 1.93 <0.05 VR homo 32 37 0.15 <0.05
Asian WT homo 314 308 1 Middle-
eastern
WT homo 7 13 1
HT 300 256 1.15 0.23 HT 67 21 5.93 <0.05
VR homo 157 69 2.23 <0.05 VR homo 43 26 3.07 <0.05
European WT homo 58 35 1 TaqI Total WT homo 517 500 1
HT 60 37 0.98 0.95 HT 322 281 1.11 0.31
VR homo 10 8 0.75 0.81 VR homo 89 67 1.28 0.16
Middle-
Eastern
WT homo 67 35 1 Asian WT homo 332 280 1
HT 46 25 0.96 0.9 HT 163 102 1.35 <0.05
VR homo 4 0 e e VR homo 56 34 1.39 0.16
African WT homo 132 203 1 European WT homo 49 30 1
HT 104 129 1.24 0.21 HT 65 39 1.02 0.95
VR homo 13 20 1.00 1 VR homo 14 11 0.78 0.59
African WT homo 136 190 1
HT 94 140 0.94 0.72
VR homo 19 22 1.21 0.57
WT Homo ¼ wild-type homozygous, HT ¼ heterozygous, VR ¼ variant recessive.
N. Sutaria et al. / Journal of Clinical & Translational Endocrinology 1 (2014) 151e160 157will have a similar impact on individuals of other ethnic back-
grounds. It is known that gene polymorphisms are inﬂuenced by
different ethnic, geographical, and other factors [43]. Differences in
genetic background among different races lead to differences in
each races’ respective gene pool. Hence, while a particular gene
polymorphism predominates in one race, another polymorphism
may prevail in another race. This makes it difﬁcult to apply data
from one race to all individuals across the world. Along these lines,
the TaqI polymorphism was only studied across Asian and African
populations, making it difﬁcult to apply the results to other pop-
ulations worldwide.
In order to remedy this shortcoming, it is important that further
studies be conducted in more populations across the world,
particularly those populations who are disproportionately affected
by TB. Doing so would allow us to view the impact of these poly-
morphisms over a larger and more diverse group of individuals.
In addition to VDR gene polymorphisms, polymorphisms of the
gene responsible for vitamin D binding protein (DBP) biosynthesis
may also potentially affect the cellular actions of vitamin D on TB.
For example, Martineau and colleagues reported an association
between Gc genotype and susceptibility to TB that is dependent on
vitamin D status [44].
Vitamin D supplementation and tuberculosis
Results
A total of three hundred and ﬁfty-one articles were identiﬁed
based on the initial PubMed search criteria. No additional articles
were identiﬁed from any other databases. Studies were only
included in the analysis if they were set up in a randomized
controlled trial fashion, if there was a measurement of time to
clearance of infection, and if patients were concurrently treated
with a standard anti-tuberculosis drug regimen. Studies were
excluded if the study subjects had any chronic diseases that would
lead to altered vitamin D metabolism, and if the study was con-
ducted in patients without TB. A total of seven studies [45e51] met
the inclusion and exclusion criteria (Table 4). A total of 1062 in-
dividuals participated in the seven studies combined. All studieswere published between 2006 and 2013 and, and all of them were
randomized-controlled trials investigating vitamin D supplemen-
tation versus placebo in addition to standard anti-tuberculosis drug
regimens.
Two of the studies [46,49] were conducted with a predomi-
nantly white population in the United Kingdom. Another study
included indigenous African population [50]. Yet another three
studies [45,47,48] utilized the indigenous South Asian populations
of Hyderabad, Karachi, and Jakarta. The ﬁnal study recruited sub-
jects from Mongolia [51]. Among those seven studies, six [45e50]
were performed with adult populations while the seventh study
[51] was conducted in school children.
All seven studies assessed time to clear TB infection as either the
primary outcome or a secondary outcome, with six of the studies
investigating sputum smear conversion [45e50] and the seventh
looking at tuberculin skin test (TST) conversion [51]. In addition,
several of the studies looked at other outcomes, such as change in
weight, change in height, changes in TB score, time to resolution of
chest radiograph abnormalities, and changes in expression of in-
ﬂammatory markers. All of the studies utilized a different regimen
of vitamin D for the treatment arm, ranging from daily adminis-
tration of small doses, to administration of very large doses every
few months.
Five of the seven studies [45,46,48,49,51] showed improve-
ments in the primary outcome in the vitamin D arm as compared to
the placebo arm. Time to sputum smear conversion was quicker,
and the percentage of subjects with negative sputum smear by a
certain number of weeks was greater when subjects received
vitamin D in addition to their anti-TB drug regimen. One study
showed no difference in the time to sputum smear conversion, but
did show improvement in the mean number of lung zones involved
in the vitamin D group versus the placebo group [47].
Aside from quicker clearance of TB, supplementation with
vitamin D led to other beneﬁcial results as well. Salahuddin et al.
[47] found that vitamin D supplementation improved mean weight
gain during anti-TB therapy and an improvement in the TB score.
Ganmaa et al. [51] found that supplementation with vitamin D
improved growth rates in school children.
Ta
b
le
4
V
it
am
in
D
su
p
p
le
m
en
ta
ti
on
st
u
d
y
ch
ar
ac
te
ri
st
ic
s
an
d
re
su
lt
s
A
rt
ic
le
Et
h
n
ic
it
y
St
u
d
y
p
op
u
la
ti
on
M
ai
n
en
d
p
oi
n
ts
In
te
rv
en
ti
on
O
u
tc
om
es
K
ot
a
et
al
.
(2
01
1)
[4
5]
So
u
th
A
si
an
30
in
d
iv
id
u
al
s
ag
e
>
15
,n
ew
ly
d
ia
gn
os
ed
p
u
lm
on
ar
y
TB
,
u
n
co
n
tr
ol
le
d
D
M
an
d
25
(O
H
)D
D
<
20
n
g/
m
L
n1
¼
15
(o
ra
l
ch
ol
ec
al
ci
fe
ro
l
60
,0
00
U
/w
k)
n2
¼
15
(n
o
vi
ta
m
in
D
)
Ti
m
e
to
ac
h
ie
ve
sp
u
tu
m
sm
ea
r
co
n
ve
rs
io
n
60
,0
00
IU
a
of
ch
ol
ec
al
ci
fe
ro
l
p
er
w
ee
k
p
lu
s
qu
ad
ru
p
le
th
er
ap
y
fo
r
TB
or
p
la
ce
bo
p
lu
s
qu
ad
ru
p
le
th
er
ap
y
Sp
u
tu
m
sm
ea
r
co
n
ve
rs
io
n
in
6
w
ee
ks
fo
r
vi
ta
m
in
D
gr
ou
p
ve
rs
u
s
8
w
ee
ks
fo
r
p
la
ce
bo
gr
ou
p
M
ar
ti
n
ea
u
et
al
.
(2
01
1)
[4
6]
M
ix
ed
e
A
si
an
,A
fr
ic
an
,
an
d
C
au
ca
si
an
12
6
in
d
iv
id
u
al
s
ag
e
>
18
,w
it
h
ou
t
h
yp
er
ca
lc
em
ia
,w
it
h
n
ew
ly
d
ia
gn
os
ed
p
u
lm
on
ar
y
TB
n1
¼
62
(v
it
am
in
D
3
)
n2
¼
64
(p
la
ce
bo
)
Ti
m
e
to
ac
h
ie
ve
sp
u
tu
m
sm
ea
r
co
n
ve
rs
io
n
4
d
os
es
of
2.
5
m
g
of
vi
ta
m
in
D
gi
ve
n
at
7,
14
,2
8,
an
d
42
d
ay
s
in
ad
d
it
io
n
to
an
ti
-T
B
re
gi
m
en
or
p
la
ce
bo
in
si
m
ila
r
d
os
es
as
ab
ov
e
in
ad
d
it
io
n
to
an
ti
-T
B
re
gi
m
en
M
ea
n
ti
m
e
to
sp
u
tu
m
sm
ea
r
co
n
ve
rs
io
n
w
as
36
d
ay
s
in
th
e
vi
ta
m
in
D
gr
ou
p
ve
rs
u
s
43
.5
d
ay
s
in
th
e
p
la
ce
bo
gr
ou
p
Sa
la
h
u
d
d
in
et
al
.(
20
13
)
[4
7]
So
u
th
A
si
an
25
9
in
d
iv
id
u
al
s
ag
e
>
16
w
it
h
n
ew
ly
d
ia
gn
os
ed
p
u
lm
on
ar
y
TB
n1
¼
13
2
(v
it
am
in
D
3
)
n2
¼
12
7
(p
la
ce
bo
)
W
ei
gh
t
ga
in
R
es
ol
u
ti
on
of
ch
es
t
ra
d
io
gr
ap
h
ab
n
or
m
al
it
ie
s
W
h
ol
e
bl
oo
d
ce
ll
an
ti
ge
n
-
st
im
u
la
te
d
IF
N
-g
re
sp
on
se
Pe
rc
en
t
sp
u
tu
m
sm
ea
r
co
n
ve
rs
io
n
by
12
w
ee
ks
Im
p
ro
ve
m
en
ts
in
TB
sc
or
e
2
d
os
es
of
60
0,
00
0
IU
at
in
it
ia
ti
on
an
d
1
m
on
th
of
vi
ta
m
in
D
or
p
la
ce
bo
in
si
m
ila
r
d
os
es
as
ab
ov
e
in
ad
d
it
io
n
to
an
ti
-T
B
re
gi
m
en
M
ea
n
w
ei
gh
t
ga
in
4.
02
kg
in
vi
ta
m
in
D
ar
m
ve
rs
u
s
2.
61
kg
in
p
la
ce
bo
ar
m
(p
<
0.
05
)
M
ea
n
n
u
m
be
r
of
lu
n
g
zo
n
es
in
vo
lv
ed
by
C
X
R
1.
35
in
vi
ta
m
in
D
ar
m
ve
rs
u
s
1.
82
in
p
la
ce
bo
ar
m
(p
<
0.
05
)
M
TB
-s
ti
m
u
la
te
d
IF
N
-g
le
ve
ls
30
92
p
g/
m
L
in
vi
ta
m
in
D
ar
m
ve
rs
u
s
29
87
p
g/
m
L
in
p
la
ce
bo
ar
m
(p
¼
0.
5)
Sp
u
tu
m
sm
ea
r
co
n
ve
rs
io
n
by
12
w
ee
ks
81
.8
%
in
vi
ta
m
in
D
ar
m
ve
rs
u
s
81
.2
%
in
p
la
ce
bo
ar
m
(n
ot
st
at
is
ti
ca
lly
si
gn
iﬁ
ca
n
t)
TB
sc
or
e
re
d
u
ct
io
n
by
3.
19
in
vi
ta
m
in
D
ar
m
ve
rs
u
s
2.
79
in
p
la
ce
bo
ar
m
N
u
rs
ya
m
et
al
.
(2
00
6)
[4
8]
So
u
th
A
si
an
67
in
d
iv
id
u
al
s
ag
ed
15
e
59
w
it
h
n
ew
ly
d
ia
gn
os
ed
p
u
lm
on
ar
y
TB
n1
¼
34
(v
it
am
in
D
)
n2
¼
33
(p
la
ce
bo
)
Pe
rc
en
t
sp
u
tu
m
sm
ea
r
co
n
ve
rs
io
n
by
6
w
ee
ks
0.
25
m
g/
d
ay
of
vi
ta
m
in
D
3
or
p
la
ce
bo
d
u
ri
n
g
in
it
ia
l6
w
ee
ks
of
tr
ea
tm
en
t
w
it
h
an
ti
-T
B
m
ed
ic
at
io
n
Sp
u
tu
m
sm
ea
r
co
n
ve
rs
io
n
by
6
w
ee
ks
w
as
10
0%
in
vi
ta
m
in
D
ar
m
ve
rs
u
s
76
.7
%
in
th
e
p
la
ce
bo
ar
m
(p
¼
0.
00
2)
C
ou
ss
en
s
et
al
.
(2
01
2)
[4
9]
U
n
sp
ec
iﬁ
ed
95
in
d
iv
id
u
al
s
w
it
h
n
ew
ly
d
ia
gn
os
ed
p
u
lm
on
ar
y
TB
n1
¼
44
(v
it
am
in
D
)
n2
¼
51
(p
la
ce
bo
)
Ti
m
e
to
sp
u
tu
m
sm
ea
r
co
n
ve
rs
io
n
2.
5
m
g
of
vi
ta
m
in
D
3
gi
ve
n
ev
er
y
2
w
ee
ks
fo
r
a
to
ta
l
of
4
d
os
es
or
p
la
ce
bo
,i
n
ad
d
it
io
n
to
st
an
d
ar
d
an
ti
-T
B
re
gi
m
en
Sp
u
tu
m
sm
ea
r
co
n
ve
rs
io
n
by
23
d
ay
s
in
vi
ta
m
in
D
ar
m
ve
rs
u
s
36
d
ay
s
in
p
la
ce
bo
ar
m
(p
¼
0.
04
)
W
ej
se
et
al
.
(2
00
9)
[5
0]
A
fr
ic
an
36
5
in
d
iv
id
u
al
s
w
it
h
n
ew
ly
d
ia
gn
os
ed
p
u
lm
on
ar
y
TB
w
er
e
st
u
d
ie
d
.
28
1
su
bj
ec
ts
co
m
p
le
te
d
th
e
12
m
on
th
s
fo
llo
w
-u
p
.
n1
¼
13
6
(v
it
am
in
D
)
n2
¼
14
5
(p
la
ce
bo
)
TB
sc
or
e
re
d
u
ct
io
n
12
-m
on
th
m
or
ta
lit
y
Ti
m
e
to
sp
u
tu
m
sm
ea
r
co
n
ve
rs
io
n
10
0,
00
0
IU
of
vi
ta
m
in
D
3
at
in
it
ia
ti
on
,5
m
on
th
s,
an
d
8
m
on
th
s
or
p
la
ce
bo
,i
n
ad
d
it
io
n
to
st
an
d
ar
d
an
ti
-T
B
m
ed
ic
at
io
n
s
N
o
d
if
fe
re
n
ce
in
TB
sc
or
e,
12
-m
on
th
m
or
ta
lit
y,
or
sp
u
tu
m
sm
ea
r
co
n
ve
rs
io
n
ti
m
es
be
tw
ee
n
th
e
tw
o
ar
m
s
G
an
m
aa
et
al
.
(2
01
2)
[5
1]
A
si
an
In
it
ia
lly
,1
20
sc
h
oo
lc
h
ild
re
n
ag
ed
12
e
15
w
er
e
st
u
d
ie
d
.H
ow
ev
er
,o
n
ly
11
7
ch
ild
re
n
co
m
p
le
te
d
th
e
6
m
on
th
s
fo
llo
w
-u
p
.
n1
¼
59
(v
it
am
in
D
)
n2
¼
58
(p
la
ce
bo
)
TS
T
co
n
ve
rs
io
n
C
h
an
ge
in
se
ru
m
25
(O
H
)D
le
ve
ls
H
ei
gh
t
80
0
IU
vi
ta
m
in
D
3
or
p
la
ce
bo
d
ai
ly
fo
r
6
m
on
th
s
TS
T
co
n
ve
rs
io
n
in
5
ch
ild
re
n
(1
1%
)
in
vi
ta
m
in
D
ar
m
ve
rs
u
s
11
(2
7%
)
in
p
la
ce
bo
ar
m
In
cr
ea
se
in
se
ru
m
25
(O
H
)D
by
m
ea
n
of
12
.7
in
vi
ta
m
in
D
ar
m
ve
rs
u
s
2.
3
in
th
e
p
la
ce
bo
ar
m
M
ea
n
in
cr
ea
se
in
st
at
u
re
2.
9

1.
6
cm
in
vi
ta
m
in
D
ar
m
ve
rs
u
s
2.
0

1.
7
cm
in
p
la
ce
bo
ar
m
a
40
IU
is
eq
u
iv
al
en
t
to
1
m
g
of
ch
ol
ec
al
ci
fe
ro
l.
N. Sutaria et al. / Journal of Clinical & Translational Endocrinology 1 (2014) 151e160158
N. Sutaria et al. / Journal of Clinical & Translational Endocrinology 1 (2014) 151e160 159One study [50] showed no signiﬁcant difference in time to
sputum smear conversion between the vitamin D and placebo
groups. This study also showed no difference in changes in TB score
or 12-month mortality rates.
Discussion
Our review ﬁnds that supplementation with vitamin D in pa-
tients with TB undergoing treatment leads to improved clinical
outcomes. The addition of vitamin D to standard anti-tuberculosis
drug regimen results in faster clearance of the infection. Partici-
pants of these clinical trials experienced no signiﬁcant side effects
from the vitamin D supplements, thus indicating that vitamin D at
the doses used are safe.
It should be noted that each clinical trial utilized different doses
and administration regimens. It is notable that regardless of the dose,
the majority of the studies showed beneﬁts from vitamin D supple-
mentation. Thus, vitaminDwill produce anoticeable effect regardless
of the dosing scheme. For instance, according to the studies reviewed,
dosingat10,000 IU (0.25mg)dailywillhave similareffects on treating
tuberculosis infectionasdosingat 60,000 IU (1.5mg) everyweek. This
allows the dosing to be modiﬁed to ﬁt the particular individual’s
preferences while still being effective.
The study by Wejse et al. [50] showed no beneﬁt to treatment
with vitamin D in patients with TB. In this trial, subjects were ran-
domized to receive 100,000 IU (2.5 mg) of vitamin D at initiation, 5
months, and 8months. The authors of this study speculated that this
particular dosing regimenwas not effective. They further stated that
either the dose concentrationwas suboptimal or the dosing interval
was too long, thus failing to allow circulating 25(OH)D to reach its
effective level. This, coupledwith the fact that serum25(OH)D levels
were only measured prior to administration of the next dose, may
have resulted in a lack of clinical effect from vitamin D.
While six of the seven studies looked at vitamin D supplemen-
tation in addition to anti-tuberculosis therapy in adults, the seventh
study [51] investigated the effect of vitamin D supplementation in
schoolchildren on risk of acquiring tuberculosis. TSTconversionwas
less frequent in children receiving vitamin D versus those receiving
placebo. This ﬁnding correlates with a previously conducted study
in adults [52] showing that TSTconversionwas less frequent among
adults with a sufﬁcient serum 25(OH)D level. With this information,
we can further decrease the incidence of TB by supplementing
children and adult alike with vitamin D, especially in areas heavily
burdened by this disease.
Conclusions
The implication of vitamin D on TB infection has a long history.
Our analysis reported here demonstrates the impacts of serum
25(OH)D levels, VDR polymorphisms, and vitamin D supplementa-
tion on the risk of acquiring TB and on the outcomes of TB infections.
An increased risk of TB was observed among the individuals with
lower serum vitamin D levels. Additionally, certain VDR poly-
morphisms, including the heterozygous and autosomal recessive
forms of the four SNPs (ApaI, BsmI, FokI, and TaqI) that we analyzed,
have shown an association with the increased risk of acquiring TB.
Finally, vitamin D supplementation appears to have a positive effect
on TB outcomes, particularly with regard to the length of infection.
Due to the fact that studies analyzed did not report their results in a
uniformmanner and no raw data are available for these studies, we
were unable to conduct a meta-analysis of the data. While the
ﬁndings in this review show a potential impact of vitamin D on TB
infection, more well-designed clinical trials are needed in order to
fully characterize the effect, particularly with regard to the VDR
polymorphisms and vitamin D supplementation [53]. Vitamin D has
been identiﬁed as an important agent in preventing many differentinfections and oncologic processes in the human body. Further
characterization of its effects and impacts on these illnesses will
allow us to develop improved treatment methods for TB in the
future, as well as other chronic diseases.Acknowledgments
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